更年期综合征患者雌激素替代治疗对胰岛素样生长因子-1及骨密度的影响

摘要
图/表
参考文献(18)
相关文章 (3)

全文: PDF (0 KB) HTML (39 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨更年期综合征患者雌激素替代治疗前后血清IGF－1、骨密度变化。方法选取2014年6月～2016年6月我院收治的100例更年期综合征患者作为研究对象，依照就诊顺序将其随机分为研究组和对照组，每组各50例。对照组患者给予常规治疗，研究组患者在常规治疗基础上，口服戊酸雌二醇片/雌二醇环丙孕酮片，连续治疗6个月。比较两组患者的Kupperman评分、总有效率、血清雌二醇、胰岛素生长因子－1水平及胫骨、桡骨超声传播速度指标变化。结果治疗后，研究组患者的改良Kupperman评分低于对照组，差异有统计学意义（P＜0.05）；研究组患者治疗总显效率（94.0%）高于对照组（78.0%），差异有统计学意义（P＜0.05）；治疗后，研究组患者的血清E2、IGF－1水平均高于对照组，差异有统计学意义（P＜0.05）；治疗后，研究组患者的胫骨、桡骨超声传播速度高于治疗前，差异有统计学意义（P＜0.05）。结论雌激素替代治疗可以增加患者雌激素水平，从而减轻更年期综合征患者的临床症状，还可增加血清胰岛素样生长因子－1水平，改善患者骨质疏松。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	马娟文
	陈伟伟
	王惠琴
	赵慧峰
	李辉

关键词 ：更年期综合征, 戊酸雌二醇片/雌二醇环丙孕酮片, 骨密度, 胰岛素样生长因子-1

Abstract：ObjectiveTo investigate the changes of serum insulin－like growth factor－1(IGF－1)and bone mineral density (BMD)before and after estrogen－replacement therapy in patients with climacteric syndrome.MethodsFrom June 2014 to June 2016,100 patients with menopausal syndrome admitted in our hospital were selected as objects and were randomly divided into research group and control group according to the order of visiting doctors,50 cases in each group.In the control group,routine treatment was used,while in the research group,on the basis of routine treatment,oraladministration of Estrdiolvlerte Tablet/Estradiol Progesterone Tablet for 6 continuous months.The Kupperman score,total effective rate,serum estradiol,insulin－like growth factor－1 (IGF－1)level,speed of ultrasound in tibia and radius were compared in research group and control group.ResultsAfter treatment,the improved Kupperman score of the research group was lower than the control group,and the difference was statistically significant(P＜0.05).The total apparent efficiency(94.0%)was higher than the control group(78.0%),and the difference was statistically significant(P＜0.05).After treatment,the serum E2and IGF－1 levels of the patients in the research group were higher than the control group,and the difference was statistically significant(P＜0.05).After treatment,the spread of tibial and radial ultrasound in the research group were higher than before treatment,and the differences were statistically significant(P＜0.05).ConclusionE-strogen－replacement therapy can increase the estrogen level,thereby alleviate the clinical symptoms of patients with menopausal syndrome,but also increase the level of serum IGF－1 and improve patient′s osteoporosis.

Key words： Menopausal syndrome Estrdiolvlerte Tablet/Estradiol Progesterone Tablet Bone mineral density Insulin－like growth factor－1

引用本文:

马娟文；陈伟伟；王惠琴；赵慧峰；李辉. 更年期综合征患者雌激素替代治疗对胰岛素样生长因子-1及骨密度的影响[J]. 中国当代医药, 2017, 24(29): 71-74.
MA Juan-wen ；CHEN Wei-wei；WANG Hui-qin； ZHAO Hui-feng；LI Hui. Influence of estrogen-replacement therapy on insulin-like growth factor-1 and bone mineral density in patients with menopausal syndrome. 中国当代医药, 2017, 24(29): 71-74.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2017/V24/I29/71

[1]	Palacios S，Mejia A，Neyro J.Treatment of the genitourinary syndrome of menopause[J].Climacteric，2015，18（1），23－29.
[2]	Maghraoui A，Rezqi A，Mrahi S，et al.Osteoporosis，vertebral fracturesandmetabolicsyndromeinpostmenopausalwomen[J].BMC Endocr Disord，2014，14（1）：93.
[3]	Stefanska A，Bergmann K，Sypniewska G.Metabolic syndrome and menopause：pathophysiology，clinical and diagnostic significance[J].Adv Clin Chem，2015，72：1－75.
[5]	蒋建发，孙爱军.中老年女性骨质疏松症流行病学现状、分类及诊断[J].中国实用妇科与产科杂志，2014，30（5）：323－326.
[7]	Rahn D，Carberry C，Sanses T，et al.Vaginal estrogen for genitourinary syndrome of menopause：a systematic review[J].Obstet Gynecol：2014，124（6）：1147－1156.
[4]	Liu W，Yang L，Kong X，et al.Meta－analysis of osteoporosis：fracture risks，medication and treatment[J].Minerva Med，2015，106（4）：203－214.
[6]	Santen R，Kagan R，Altomare C，et al.Current and evolving approaches to individualizing estrogen receptor－based therapy for menopausal women[J].J Clin Endocrinol Metab，2014，99（3）：733－747.
[8]	Stuenkel C，Davis S，Gompel A，et al.Treatment of symptoms of the menopause：an endocrine society clinical practice guideline[J].J Clin Endocrinol Metab，2015，100（11）：3975-4011.
[9]	Tao M，Shao H，Li C，et al.Correlation between the modified Kupperman index and the menopause rating scale in chinese women[J].Patient Prefer Adherence，2013，7：223-229.
[10]	Gandhi J，Chen A，Dagur G，et al.Genitourinary syndrome of menopause：an overview of clinical manifestations，pathophysiology，etiology，evaluation，and management[J].Am J Obstet Gynecol，2016，215（6）：704-711.
[11]	Indhavivadhana S，Rattanasrithong P.The relationship between bone mineral density and metabolic syndrome in peri-and post-menopausal thai women[J].Arch Gynecol Obstet，2015， 292（5）：1127-1133.
[12]	Fujita K，Roforth M，Demaray S，et al.Effects of estrogen on bone mrna levels of sclerostin and other genes relevant to bone metabolism in postmenopausal women[J].J Clin Endocrinol Metab，2014，99（1）：81-88.
[13]	Klein-NulendJ，OersR，BakkerA，etal.Bonecellmechanosensitivity，estrogen deficiency，and osteoporosis[J].J Biomech，2015，48（5）：855-865.
[14]	Lambert T，Thybo C，Lykkeboe S，et al.Combined bioavailable isoflavones and probiotics improve bone status and estrogen metabolism in postmenopausal osteopenic women：a randomized controlled trial[J].Am J Clin Nutr，2017，106（3）：99.
[15]	Streicher C，Heyny A，Andrukhova O，et al.Estrogen regulates bone turnover by targeting rankl expression in bone lining cells[J].Sci Rep，2017，7(1)：6460.
[16]	Ashpole N，Herron J，Mitschelen M，et al.IGF-1 regulates vertebral bone aging through sex-specific and time-dependent mechanisms[J].J Bone Miner Res，2016，31（2）：443-454.
[17]	Farquharson C，Ahmed S.Inflammation and linear bone growth：the inhibitory role of SOCS2 on GH/IGF-1 signaling[J].Pediatr Nephrol，2013，28（4）：547-556.
[18]	Poudel S，Bhattarai G，Kook SH，et al.Recombinant human IGF-1 produced by transgenic plant cell suspension culture enhances new bone formation in calvarial defects[J].Growth Horm IGF Res，2017，30（36）：1-10.